Clinical Trial Update: Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC) [Phase 3]

View source ↗

Summary

Phase 3 trial update of telaprevir with standard of care in hepatitis C virus-associated hepatocellular carcinoma has been terminated; results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C
• Hepatocellular Carcinoma

Drugs mentioned

• Telaprevir (telaprevir)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Infection | Phase 3 | Status: TERMINATED | Results posted: 2015-03-06